Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1538 participants.
Also called NCT02940860
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,538 participants
- Sponsor
- Registry
-
NCT02940860
-
- Other papers using this trial's data
- Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02940860. Randomized; no masking; primary purpose treatment. Start 2016-11-29 (actual); primary completion 2018-05-29 (actual). Results posted on 2020-03-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
- Condition
- Iron Deficiency Anaemia
- Condition
- Iron Deficiency Anemia
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Iron isomaltoside/ferric derisomaltose
- Intervention (Drug)
- Iron sucrose
- Lead sponsor
- Pharmacosmos A/S
Record details
- Record id
cardio:ct-nct02940860- Content hash
4564330995af117e08d83e91c796bcdcf023a763a2736e8f05462c4107403cd3